Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study

被引:359
作者
Cheung, Ka Shing [1 ]
Chan, Esther W. [2 ]
Wong, Angel Y. S. [2 ]
Chen, Lijia [1 ]
Wong, Ian C. K. [2 ,3 ]
Leung, Wai Keung [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Hong Kong, Hong Kong, Peoples R China
[3] UCL, UCL Sch Pharm, London, England
关键词
THERAPY; ASSOCIATION; ERADICATION; OMEPRAZOLE; INFECTION; SUPPRESSION;
D O I
10.1136/gutjnl-2017-314605
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy. Designs This study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists (H2RA) started within 6 months before GC were excluded to avoid protopathic bias. We evaluated GC risk with PPIs by Cox proportional hazards model with propensity score adjustment. H2RA was used as a negative control exposure. Result Among the 63 397 eligible subjects, 153 (0.24%) developed GC during a median follow-up of 7.6 years. PPIs use was associated with an increased GC risk (HR 2.44, 95% CI 1.42 to 4.20), while H2RA was not (HR 0.72, 95% CI 0.48 to 1.07). The risk increased with duration of PPIs use (HR 5.04, 95% CI 1.23 to 20.61; 6.65, 95% CI 1.62 to 27.26 and 8.34, 95% CI 2.02 to 34.41 for = 1 year, = 2 years and = 3 years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs use was 4.29 excess GC (95% CI 1.25 to 9.54) per 10 000 person-years. Conclusion Long-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 35 条
[1]   Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [J].
Chan, Esther W. ;
Lau, Wallis C. Y. ;
Leung, Wai K. ;
Mok, Michael T. C. ;
He, Ying ;
Tong, Teresa S. M. ;
Wong, Ian C. K. .
GASTROENTEROLOGY, 2015, 149 (03) :586-+
[2]   Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid [J].
Cheung, Ka-Shing ;
Seto, Wai-Kay ;
Fung, James ;
Lai, Ching-Lung ;
Yuen, Man-Fung .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2017, 8
[3]   Influenza-related hospitalizations among children in Hong Kong [J].
Chiu, SS ;
Lau, YL ;
Chan, KH ;
Wong, WHS ;
Peiris, JSM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (26) :2097-2103
[4]   Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials [J].
Ford, Alexander C. ;
Forman, David ;
Hunt, Richard H. ;
Yuan, Yuhong ;
Moayyedi, Paul .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
[5]   Overprescribing proton pump inhibitors - Is expensive and not evidence based [J].
Forgacs, Ian ;
Loganayagam, Aathavan .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7634) :2-3
[6]   Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK [J].
Garcia Rodriguez, L. A. ;
Lagergren, J. ;
Lindblad, M. .
GUT, 2006, 55 (11) :1538-1544
[7]   Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy [J].
Gu, Q. ;
Xia, H. H. X. ;
Wang, J. D. ;
Wong, W. M. ;
Chan, A. O. O. ;
Lai, K. C. ;
Chan, C. K. ;
Yuen, M. F. ;
Fung, F. M. Y. ;
Wong, K. W. ;
Lam, Sx. ;
Wong, B. C. Y. .
DIGESTION, 2006, 73 (2-3) :101-106
[8]  
HOWDEN CW, 1990, ALIMENT PHARM THER, V4, P25
[9]   Clarithromycin-Amoxycillin-Containing Triple Therapy: A Valid Empirical First-Line Treatment for Helicobacter pylori Eradication in Hong Kong? [J].
Hung, Ivan F. N. ;
Chan, Pierre ;
Leung, Sally ;
Chan, Fion S. Y. ;
Hsu, Axel ;
But, David ;
Seto, Wai Kay ;
Wong, Siu Yin ;
Chan, Chi Kuen ;
Gu, Qing ;
Tong, Teresa S. M. ;
Cheung, Ting Kin ;
Chu, Kent Man ;
Wong, Benjamin C. Y. .
HELICOBACTER, 2009, 14 (06) :505-511
[10]   Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis [J].
Janarthanan, Sailajah ;
Ditah, Ivo ;
Adler, Douglas G. ;
Ehrinpreis, Murray N. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) :1001-1010